Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure

BACKGROUND: Currently, there are a few treatment options for unresectable hepatocellular carcinoma (HCC) after progression following sorafenib (SOR) therapy, but with limited benefit. The purpose of this study was to investigate the efficacy and safety of tyrosine kinase inhibitors (TKIs) combined w...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaomi, Ding, Xiaoyan, Li, Wei, Chen, Jinglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198937/
https://www.ncbi.nlm.nih.gov/pubmed/36441192
http://dx.doi.org/10.1007/s00262-022-03324-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198937/
https://www.ncbi.nlm.nih.gov/pubmed/36441192
http://dx.doi.org/10.1007/s00262-022-03324-z

Ejemplares similares